Term
| Class of drugs you see Lactic Acidosis and Hepatic Steatosis |
|
Definition
|
|
Term
| Hyperpigmentation/skin discoloration |
|
Definition
| Emtricitabine (emtriva) (FTC) |
|
|
Term
| Fanconi Syndrome, Osteomalacia, DECREASED BMD |
|
Definition
|
|
Term
| Should NOT use with Lamivudine (3TC) |
|
Definition
|
|
Term
| Should NOT use with Emtricitabine (FTC) |
|
Definition
|
|
Term
| Can cause acute HBV exacerbation in co-infected |
|
Definition
| Lamivudine, Emtricitabine, Tenofovir |
|
|
Term
|
Definition
| Didanosine(ddl) and Abacavir (ABC) |
|
|
Term
| Only NRTI that is a problem in renal patients AND hepatic |
|
Definition
|
|
Term
| MUST take this NRTI on an empty stomach unless you take with UTF |
|
Definition
|
|
Term
| Do NOT use with Stavudine (d4t) |
|
Definition
| Didanosine (ddl) and Zidovudine (AZT) |
|
|
Term
| Do NOT use with didanosine or Zidovudine |
|
Definition
|
|
Term
| Peripheral Neuropathy, Lipoatrophy, Insulin resistance/DM, Hyperlipidemia |
|
Definition
| Zidovudine (AZT), Stavudine (d4t), Didanosine (ddl) |
|
|
Term
| Can cause optic neuritis, NRTI |
|
Definition
|
|
Term
| Bone marrow suppression, NRTI |
|
Definition
|
|
Term
|
Definition
| Etravirine (ETR), Rilpivirine |
|
|
Term
| Tablet can be dissolved in water NNRTI |
|
Definition
|
|
Term
| Higher incidence of rash (SJS, TEN) and incidence of hepatotoxicity |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Should not really use in females with CD4 > 250 and Males with a CDF > 400 |
|
Definition
|
|
Term
| INCREASED rate of virolgoic failures when HIV VL > 100,000 or CD4 < 200 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Stavudine (d4t), Zidovudine (ZDV) |
|
|
Term
| Teratogenic, avoid in women that are pregnant |
|
Definition
|
|
Term
| NNRTI that should NOT be used with PPI without spacing it |
|
Definition
|
|
Term
| Drug class has HIGHER genetic barrier to resistance than NNRTIs and INSTIs (need more virus mutation) |
|
Definition
|
|
Term
| Drug class causes Fat maldistribution, INCRASED bleeding time in hemophiliacs, Dyslipidemia and issue problems |
|
Definition
|
|
Term
| Indirect hyperbilirubinemia (jaundice or scleral icterus) |
|
Definition
|
|
Term
| Space dosing when using acid suppressing agents , PI |
|
Definition
|
|
Term
| Neprholithiasis, Cholelithiasis AND PR prolongation |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Preferred PI's for initial treatment |
|
Definition
|
|
Term
| Contains Sulfonamide moiety |
|
Definition
| Darunavir (DRV), Tipranavir, Fosamprinavir (FPV) |
|
|
Term
| MUST NEVER be given without a booster (Ritonavir) |
|
Definition
|
|
Term
| Can be given unboosted in ARV naive patients |
|
Definition
|
|
Term
| PR and QT prolongation with Significant dyslipidemia (mainly TG) |
|
Definition
| Lopinavir/Ritonavir (kaletra) |
|
|
Term
| Can dissolve tablet in water (PI) |
|
Definition
|
|
Term
| Cause significant diarrhea |
|
Definition
|
|
Term
| Highest pill burden of PIs |
|
Definition
|
|
Term
| Only PI that is NEVER boosted with Ritonavir (RTV) |
|
Definition
|
|
Term
| Hepatotoxicity, drug induced hepatitis and Fatal/Non fatal intracranial hemorrhage |
|
Definition
|
|
Term
| This class has fewer drug interactions than PI, NNRTI, MVC or EVG regimens |
|
Definition
|
|
Term
| Potential for increase in Cr Kinase, myopathy and Rhabdomyolysis |
|
Definition
|
|
Term
| Integrase inhibitor that requires food |
|
Definition
|
|
Term
| Only recommended in patients with a baseline CrCl > 70 |
|
Definition
|
|
Term
| Primarily only used in salvage therapy |
|
Definition
| Enfuvirtide (T-20) Fusion inhibitor |
|
|
Term
| Must be given Sub-Q dosing |
|
Definition
|
|
Term
| Local injection site reaction in 100% of patients |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Can ONLY give in patients that have virus using CCR5 or R5 virus, can NOT be used in anything else even if mixed receptor virus |
|
Definition
|
|
